Wockhardt announces successful USFDA inspection of Bioequivalence Centre in Aurangabad

Wockhardt announced that U. S. Food and Drug Administration ('USFDA') has carried out inspection of Bioequivalence Centre located at R&D Centre, Aurangabad during which Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited. At the end of inspection, there was Nil observation (i.e. zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations. This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre.

Powered by Capital Market - Live News